Group 2D: HER2+ Breast Cancer; Clinical Trials; Antibody-drug Conjugates

Poster #PO1-20-06: Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 +/- pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan.

Poster #PO1-04-02: ACE-Breast-03: A phase 2 study of ARX788, a novel next-generation anti-HER Antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecan.

Date

Dec 14 2023

Time

2:00 pm - 3:30 pm

Zoom Webinar

REGISTER